EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction

Amit Gaba iD, Maria Yousefi, Shreoshri Bhattacharjee, Linda Chelico iD

Journal of Virology · 2025

DOI: 10.1128/jvi.01606-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Amit Gaba und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. Hauptthemen laut MEDLINE: HIV-1, APOBEC-3G Deaminase, Cytosine Deaminase, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), Saskatchewan Health Research Foundation (SHRF), University of Saskatchewan College of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several APOBEC3 enzymes restrict HIV-1 by deaminating cytosine to form uracil in single-stranded proviral (−)DNA. However, HIV-1 Vif counteracts their activity by inducing their proteasomal degradation. This counteraction by Vif is incomplete, as evidenced by footprints of APOBEC3-mediated mutations within integrated proviral genomes of people living with HIV-1. The relative contributions of multiple APOBEC3s in HIV-1 restriction are not fully understood. Here, we investigated the activity of co-expressed APOBEC3F and APOBEC3G against HIV-1 Subtype B and Subtype C transmitted/founder viruses. We determined that APOBEC3F interacts with APOBEC3G through its N-terminal domain. We provide evidence that this results in protection of APOBEC3F from Vif-mediated degradation because the APOBEC3F N-terminal domain contains residues required for recognition by Vif. We also found that HIV-1 Subtype C Vifs, but not Subtype B Vifs, were less active against APOBEC3G when APOBEC3F and APOBEC3G were co-expressed. Consequently, when APOBEC3F and APOBEC3G were expressed together in a single cycle of HIV-1 replication, only HIV-1 Subtype C viruses showed a decrease in relative infectivity compared to when APOBEC3G was expressed alone. Inspection of Vif amino acid sequences revealed that differences in amino acids adjacent to conserved sequences influenced the Vif-mediated APOBEC3 degradation ability. Altogether, the data provide a possible mechanism for how combined expression of APOBEC3F and APOBEC3G could contribute to mutagenesis of HIV-1 proviral genomes despite the presence of Vif and provide evidence for variability in the Vif-mediated APOBEC3 degradation ability of transmitted/founder viruses. IMPORTANCE APOBEC3 enzymes suppress HIV-1 infection by inducing cytosine deamination in proviral DNA but are hindered by HIV-1 Vif, which leads to APOBEC3 proteasomal degradation. Moving away from traditional studies that used lab-adapted HIV-1 Subtype B viruses and singular APOBEC3 enzymes, we examined how transmitted/founder isolates of HIV-1 replicated in the presence of APOBEC3F and APOBEC3G. We determined that APOBEC3F interacts with APOBEC3G through its N-terminal domain and that APOBEC3F, like APOBEC3G, has Vif-mediated degradation determinants in the N-terminal domain. This enabled APOBEC3F to be partially resistant to Vif-mediated degradation. We also demonstrated that Subtype C is more susceptible than Subtype B HIV-1 to combined APOBEC3F/APOBEC3G restriction and identified Vif variations influencing APOBEC3 degradation ability. Importantly, Vif amino acid variation outside of previously identified conserved regions mediated APOBEC3 degradation and HIV-1 Vif subtype-specific differences. Altogether, we identified factors that affect susceptibility to APOBEC3F/APOBEC3G restriction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1APOBEC-3G DeaminaseCytosine DeaminaseHIV InfectionsHumansvif Gene Products, Human Immunodeficiency VirusHEK293 CellsHost-Pathogen InteractionsVirus ReplicationProviruses

Stichwörter der Autor:innen

APOBEC3HIVrestriction factortransmitted/founder

Substanzen

APOBEC-3G DeaminaseAPOBEC3F protein, humanvif Gene Products, Human Immunodeficiency VirusAPOBEC3G protein, humanCytosine Deaminasevif protein, Human immunodeficiency virus 1

Autor:innen und Institutionen

  • Department of Biochemistry, Microbiology, and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

ORCID-Profile: Amit Gaba, Linda Chelico

Förderung

  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • Saskatchewan Health Research Foundation (SHRF)
  • University of Saskatchewan College of Medicine

Zitieren

APA

Gaba, A., Yousefi, M., Bhattacharjee, S., & Chelico, L. (2025). Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction. Journal of Virology. https://doi.org/10.1128/jvi.01606-24

Vancouver

Gaba A, Yousefi M, Bhattacharjee S, Chelico L. Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction. Journal of Virology. 2025. doi:10.1128/jvi.01606-24

BibTeX
@article{Gaba2025,
  author = {Gaba, Amit and Yousefi, Maria and Bhattacharjee, Shreoshri and Chelico, Linda},
  title = {Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01606-24}
}
Kostenlos starten →